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Although laboratory investigation is essential for diagnosis and 
management, it also introduces advances in science, thereby 
enhancing patient care. Investigations should not, however, strain 
limited resources. Modest changes in the lipid profile impact on 
atherosclerosis risk, and undesirable values, are highly prevalent 
in both sexes worldwide.[1] More extreme dyslipidaemias identify 
individuals at higher risk of atherosclerosis. Lipid disorders, 
including pancreatitis and metabolic disorders, should also be 
considered in other clinical settings. The purpose of this article is to 
provide the medical practitioner with an understanding of laboratory 
investigations in lipidology. 
Lipids
Lipids are water-insoluble compounds including sterols (cholesterol) 
and fatty acids (FAs) (typically esterified as triglycerides and phospho-
lipids). Lipids serve many functions in the cell: membrane formation, 
steroid hormone and bile acid production, and the provision and 
storage of energy. Lipids are transported as lipoproteins, but albumin 
transports non-esterified FAs. 
Fatty acids 
FAs are carboxylic acids comprising mostly saturated but also 
mono- or polyunsaturated carbon to carbon bonds. Short-chain 
(≤6 C) and medium-chain (8 - 12 C) FAs are generally metabolised 
intracellularly. Long-chain (14 - 22 C) FAs are found in triglycerides 
and phospholipids. The latter influences inflammation and 
thrombosis through prostaglandins. Essential FAs (linoleic acid and 
alpha-linolenic acid) are sourced from plants. Plants also contain 
very-long-chain FAs and branch-chain FAs, which are metabolised 
in peroxisomes. Dietary FAs, as well as those generated in the gut 
microbiota, significantly influence health.[2]
Triglycerides
Triglycerides consist of three long-chain FAs esterified to glycerol. 
In animals they form fats. In plants they form oils, as unsaturated 
bonds confer liquid properties. Triglycerides are also synthesised in 
hepatocytes and adipocytes. During fasting, free FAs mobilise from 
adipocytes to the liver, which releases triglycerides and ketones as 
sources of energy. 
Phospholipids
Phospholipids resemble triglycerides, but a terminal FA is substituted 
by a phosphate and choline, ethanolamine, serine or inositol. 
Phospholipids are the main structural component of cell membranes, 
coat lipoproteins and emulsify dietary fat. 
Sterols
Cholesterol is vital to animal cell membranes, functions in signalling 
during embryogenesis, and is the substrate for steroid hormone and 
bile acid (BA) synthesis. Cholesterol is absorbed from the diet or 
synthesised de novo by cells. Beta-hydroxy beta-methylglutaryl 
(HMG)-CoA reductase, the rate-limiting enzyme in biosynthesis, 
is upregulated by cholesterol depletion in cells and inhibited by 
statins. Oxysterols regulate sterol and other metabolic pathways, 
and may be found in atherosclerotic plaques. Precursor sterols 
and plant sterols (beta-sitosterol and campesterol), BAs and an 
intermediate product, cholestanol, occur in trace quantities in 
plasma. BAs, via signalling pathways, may also regulate glucose 
and lipid metabolism, and energy homeostasis. The enterohepatic 
circulation of BAs is disrupted in liver dysfunction, resulting in 
hypercholanaemia. 
Lipoproteins
Lipoproteins are spherical particles comprising a core of triglycerides 
and cholesterol esters (CEs), and a surface of phospholipid 
and unesterified cholesterol (UC) in which apoproteins reside. 
Apoproteins facilitate lipoprotein assembly, modulation and 
clearance. Lipoproteins are classified by ultracentrifugation into 
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five major types, with increasing density 
and decreasing size: chylomicrons (CMs), 
very low-density lipoprotein (VLDL), 
intermediate-density lipoprotein (IDL), 
low-density lipoprotein (LDL) and 
high-density lipoprotein (HDL). The 
density of the particle depends on the 
lipid (less dense) and protein (denser) 
content. During fasting, VLDL carries the 
majority of triglyceride and LDL carries 
the majority of cholesterol. Circulating 
CMs after a meal raise triglyceride levels. 
In the circulation, lipoproteins undergo 
continuous modification in a flux through 
interconnected pathways (Fig. 1). 
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Fig. 1. Lipoprotein metabolic pathways. Exogeneous pathway: after the intestinal absorption and assembly on apo B48 of dietary fatty acids and sterols, 
chylomicrons transport lipids to tissues and finally the liver. Endogeneous pathway: the liver assembles triglycerides and cholesterol on apo B100 in very 
low-density lipoprotein (VLDL) during fasting, with recycling of remnants. Low-density lipoprotein (LDL) pathway: the endogeneous pathway ends with 
the supply of cholesterol to tissues on demand through LDL-receptor expression. Reverse cholesterol transport pathway: moves cholesterol from cells to 
the liver either directly (scavenger receptor) or indirectly (VLDL) by cholesterol ester transfer protein. Apo A4 synthesised in enterocytes, as well as other 
apoproteins, assimilates in high-density lipoprotein. Lipoprotein (a) pathway: highly variable in humans. Albumin pathway: non-esterified fatty acid complex 
with albumin in plasma. (A1, A4, B48, B100, E = apoproteins; ABCA1 and ABCG5/G8 = ATP-binding casette transporter proteins; CE = cholesterol ester; 
CETP = cholesterol ester transfer protein; CM = chylomicron; FA = fatty acid; HSPG = heparan sulphate proteoglycans; HDL = high-density lipoprotein; 
IDL = intermediate-density lipoprotein; LCAT = lecithin:cholesterol acyl transferase; LPL = lipoprotein lipase; LDL = low-density lipoprotein; LDLR = LDL 
receptor; LDLRP = LDL receptor-like protein; NEFA = non-esterified fatty acid; SR = scavenger receptor B1; UC = unesterified cholesterol; VLDL = very 
low-density lipoprotein.)
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In the exogenous pathway, lipoprotein lipase (LPL), held on 
the vascular endothelium by heparan sulphate proteoglycans 
(HSPGs), hydrolyses triglycerides (in the presence of apo protein C2 
(apo C2)), releasing FAs and CM-remnants in the process. 
Excessive phospholipid on shrinking CMs can depart with apo A1, 
forming HDL. 
In the endogenous pathway, hepatocytes assemble triglycerides 
onto apo B100, forming VLDL. Similar to CMs, circulating VLDL 
undergoes lipolysis, resulting in remnants, while generating some 
HDL. These remnants, IDL, are cleared by the liver through apo E 
binding HSPG, LDL receptor-like protein (LRP) and the LDL 
receptor (LDLR). Some remnants are processed to LDL, on which 
apo B100, now the sole apoprotein, is in the correct conformation to 
bind the LDLR (expressed by cells that require cholesterol). 
HDL transports cholesterol in the reverse pathway, predominantly 
with apo A1, which assimilates phospholipid, but also apo A4 
and apo E. Cells respond to apo A1 by releasing cholesterol and 
phospholipid through adenosine-binding cassette transporter protein 
(ABCA1). Lecithin:cholesterol acyl transferase (LCAT) enriches 
HDL with cholesterol by forming CE that moves to its core. CEs 
may be exchanged by cholesterol ester transfer protein (CETP) to 
triglyceride-rich lipoproteins, destined for the liver. HDL can also 
deliver CEs directly to the liver via scavenger receptor B1 (SR). 
Lipoprotein (a) (Lp (a)) resembles LDL but contains covalently 
bound apo (a). Being homologous to plasmin, it may impair 
thrombolysis, explaining its modest independent impact on athero-
sclerosis. 
Laboratory investigations
Most lipidological investigation assesses cardiovascular disease 
(CVD) risk and monitors treatment response. Atherosclerosis is 
associated with increasing LDL and remnants and decreasing HDL 
concentrations. Hypertriglyceridaemia predicts pancreatitis. Less 
commonly, genetic disorders with severe dyslipidaemias may occur. 
Rarely, FAs and sterol disorders may be present without disturbing 
the conventional lipid profile.
Sampling
Approximately 3 mL of blood for routine analysis is collected in a 
plain tube (yellow- or red-capped) to analyse the serum lipids. CMs 
and VLDL scatter light and result in turbidity (triglyceride >2.5 mmol/L). 
Frank lipaemia indicates severe hypertriglyceridaemia (trigly -
ceride >10 mmol/L). In effusions, cholesterol may differentiate 
transudates from exudates; triglyceride may indicate chylothorax.[3,4] 
Routine investigations
Secondary causes for dyslipidaemias should be excluded or treated 
before full lipidological work-up (Table 1). Hypercholesterolaemia 
may be due to nephrotic syndrome or hypothyroidism. 
Hypertriglyceridaemia may be caused by alcohol or diabetes.
The conventional profile comprises triglyceride, total cholesterol 
(TC) and HDL cholesterol, which are measured by enzymatic 
colorimetric assays, and LDL cholesterol, which can be calculated 
in fasting samples or measured directly. Cholesterol esterase ensures 
that cholesterol oxidase reacts with all cholesterol. In homogenous 
HDL cholesterol assays, dextran sulphate selectively forms water-
soluble complexes with LDL, VLDL and CMs, which resist modified 
enzymes. 
Clinically insignificant differences are found in the TC and 
HDL cholesterol results of fasting or non-fasting individuals. 
Triglycerides are traditionally measured in the fasting state because 
the Friedewald equation (Box 1) will approximate the LDL cholesterol 
when triglyceride values are ˂4.5 mmol/L, provided that remnants, 
Lp (a) and Lp X are absent. LDL cholesterol can be measured directly 
by homogenous assays or ultracentrifugation.
TC results can vary in an individual by as much as 14% owing to 
factors such as stress, illness, posture, seasonal variation and inter-
lab variability.[5] More than one TC measurement is advised when 
decisions are to be made in moderate dyslipidaemias. Even greater 
variability may be demonstrated by HDL cholesterol measurement.[6] 
Extended lipid profile
Apo A1, apo B and Lp (a) are measured immunoturbidimetrically. 
Apo A1 is the major protein of HDL, whereas apo B is the major 
protein of LDL, accounting for 95% of plasma apo B. Apo B 
measurements are a surrogate for lipoprotein particle concentration 
(number). For the same LDL concentration, small LDL will have a 
larger particle number.[7] Strong associations between CVD and LDL 
particle number, or high concentrations of Lp (a), provide a rationale 
for advanced testing in CVD management. 
Special investigations
Electrophoresis
Routine ultracentrifugation is impracticable, but electrophoresis 
can demonstrate lipoprotein fractions in small sample volumes 
and remains useful for the diagnosis of several dyslipidaemias. 
The traditional agarose gels can diagnose Fredrickson type 1 
(chylomicronaemia), type 3 (dysbetalipoproteinaemia), Lp X and 
sulphated cholesterol in X-linked ichthyosis. Lp X is an abnormal 
lipoprotein that is formed in cholestasis or LCAT deficiency. 
Deficiencies or absences of lipoproteins are also readily demonstrated. 
This includes abetalipoproteinaemia, hypobetalipoproteinaemia and 
Tangier disease (analphalipoproteinaemia). 
Non-denaturing polyacrylamide gel electrophoresis is 
less well established but discriminates LDL sizes and detects 
dysbetalipoproteinaemia well.[8] Small and dense LDL is associated 
with insulin resistance and diabetes, is more susceptible to oxidation 
and enters arterial walls more readily. CVD risk is increased two- 
to three-fold.[7,9,10] Nuclear magnetic resonance spectroscopy, 
density gradient ultracentrifugation and ion mobility analysis also 
characterise LDL further.
Genetic testing
Genotyping should be used judiciously and only where it impacts 
management. This includes preconception counselling and 
identifying carriers of severe recessive disorders. Genetic diagnosis, 
along with functional fibroblast studies, is warranted if homozygous 
familial hypercholesterolaemia (FH) is considered. With decreasing 
costs of sequencing and the future possibility of genome editing, 
genotyping may become routine.
Sterols
Unlike cholesterol, present in millimolar concentration, its precursors, 
products and plant analogues are only found at micromolar 
concentration in plasma. Non-cholesterol sterols are typically 
detected by gas chromatography-mass spectrometry (GC-MS) or 
GC-flame ionisation detection (GC-FID). Cholesterol biosynthetic 
Box 1. Friedewald equation to calculate LDLC (mmol/L)
LDLC = TC − HDLC − (TG/2.2), where (TG/2.2) is an estimation 
of VLDLC
LDLC = low-density lipoprotein cholesterol; TC = total cholesterol; HDLC = high-
density lipoprotein cholesterol; TG = triglyceride; VLDL = very low-density lipoprotein 
cholesterol.
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errors elevating levels of 7-dehydrocholesterol, lathosterol or 
desmosterol, should be considered in the setting of congenital 
malformations and impaired development. A spectrophotometric 
assay for 7-dehydrocholesterol is less expensive to diagnose Smith-
Lemli-Opitz syndrome.[11]
Markedly elevated levels of sitosterol and campesterol confirm 
phytosterolaemia, an autosomal recessive disorder mimicking FH. 
The adenosine triphosphate (ATP)-binding cassette sub-family G5 or 
G8 mutations prevent the excretion of plant sterols.
Cerebrotendinous xanthomatosis is an autosomal recessive disease 
caused by a deficiency of sterol 27-hydroxylase. Impaired BA 
synthesis is accompanied by increased formation of cholestanol. 
There may be massive tendon xanthomata, leukodystrophy and 
cataracts without significant dyslipidaemia. BA supplements can be 
of benefit because they suppress BA synthesis.
Fatty acids 
Determining the profile of physiologically and nutritionally 
Table 1. Dyslipidaemias and dyslipoproteinaemias with their primary and secondary causes
Lipid (mmol/L) Lipoprotein (lipid) involved Secondary causes Primary causes
TG 1.7 - 2.5 VLDL Dysglycaemia
Alcohol
Obesity
Polygenic variants (mild)
Corticosteroids
Retinoids
Monogenic variants (e.g. LPL deficiency)
TG 2.5 - 5.0 VLDL ± IDL Dysglycaemia
Alcohol
Obesity
Corticosteroids
Retinoids
Polygenic variants (mild)
Monogenic variants 
(e.g. LPL deficiency) 
Dysbetalipoproteinaemia
TG 5.0 - 15.0 (often with 
hypercholesterolaemia) 
VLDL, IDL ± CM Dysglycaemia
Alcohol
Obesity
Corticosteroids
Retinoids +
genetic predisposition 
Polygenic variants (mild)
Monogenic variants 
(e.g. LPL deficiency) 
Dysbetalipoproteinaemia
TG >15.0 (usually with 
hypercholesterolaemia) 
CM, VLDL Genetic predisposition + 
metabolic stress
Polygenic variants (mild)
Monogenic variants 
(e.g. LPL deficiency), more commonly 
monogenic 
(LPL, apo C2 apo Av, LMF-1, 
GPI-HBP-1)
Dysbetalipoproteinaemia
TC <2.0 LDL, VLDL, CM Acute-phase response
Malnutrition
Malabsorption
Apo B truncations
MTTP deficiency
TC 2.0 - 5.0 (atherosclerosis 
 setting)
HDL (<0.7 mmol/L)
Lp (a)
Acute-phase response ABCA1, LCAT, apo A1
Genetic variants
TC 2.0 - 5.0 (other clinical 
presentations)
Unusual lipids
VLCFA
BCFA
Cholesterol sulphate
Cholestanol
Not applicable
Adrenoleukodystrophy
Refsum disease
X-linked ichthyosis
CTX
TC 5.0 - 7.5 LDL (rarely HDL elevates TC) Diet
Hypothyroidism
Nephrotic syndrome
Lp X
Polygenic
Hyperalphalipoproteinaemia: CETP, apo C3, EL 
and SR-B1 deficiencies
TC 7.5 - 15.0 LDL Lp X
Nephrotic syndrome
Hypothyroidism
FH: LDL >5.0 mmol/L
LDL-R, FDB and ARH, PCSK9 gain of function 
mutations
Phytosterolaemia
TC >15.0 LDL Lp X Homozygous FH, ARH
Phytosterolaemia 
TG = triglyceride; VLDL = very low-density lipoprotein; LPL = lipoprotein lipase; IDL = intermediate-density lipoprotein; CM = chylomicron; apo C2 = apolipoprotein C2; apo Av = apo-
lipoprotein Av; LMF-1 = lipoprotein maturation factor 1; GPI-HBP-1 = glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1; TC = total cholesterol; LDL = low-
density lipoprotein; apo B = apolipoprotein B; MTTP = microsomal triglyceride transfer protein; HDL = high-density lipoprotein; Lp (a) = lipoprotein (a); VLCFA = very-long-chain fatty acids; 
BCFA = branched-chain fatty acids; ABCA1 = ATP-binding cassette subfamily A member 1; LCAT = lecithin-cholesterol acyltransferase; apo A1 = apolipoprotein A1; CTX = cerebrotendinous 
xanthomatosis; Lp X = lipoprotein X; CETP = cholesteryl ester transfer protein; apo C3 = apolipoprotein C3; EL = endothelial lipase; SR-B1 = scavenger receptor class B type 1; FH = familial 
hypercholesterolaemia; LDLR = low-density lipoprotein receptor; FDB = familial defective apolipoprotein B; ARH = autosomal recessive hypercholesterolaemia; PCSK9 = proprotein convertase 
subtilisin/kexin type 9.
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important FAs is of limited use in clinical practice. However, certain 
rare peroxisomal disorders are diagnosed by identifying abnormal 
FAs. Very-long-chain FAs impair adrenal and neuronal function in 
X-linked adrenoleukodystrophy. In Refsum disease, branched-chain 
FAs accumulate, resulting in neurological, cutaneous and ophthalmic 
manifestations.
Enzyme analysis
Enzyme analysis is rarely required but can shed light on disease 
mechanisms and improve management. LPL deficiency is demonstrated 
in plasma by displacement of LPL from heparan sulphate proteoglycans 
on endothelial cells after heparin injection. The autosomal recessive 
disorder, characterised by marked hyperchylomicronaemia and 
a corresponding hypertriglyceridaemia, can be due to errors in 
LPL, its cofactors apo C2 and apo A5, or its transporters lipase 
maturation factor 1 and glycosylphosphatidylinositol-anchored high-
density lipoprotein-binding protein 1 (GPI-HBP-1). If apo C2 is 
deficient, supplementation by fresh-frozen plasma can alleviate 
severe hypertriglyceridaemia and pancreatitis. 
Other enzyme studies of interest include LCAT activity in the 
setting of low HDL cholesterol, and lysosomal acid lipase in Wolman 
disease and CE storage disease. The latter presents as a mixed 
hyperlipidaemia with severe liver enzyme derangement, and responds 
to recombinant lysosomal acid lipase. 
Cell culture
Fibroblast cultures are performed at few centres but may be crucial 
for diagnosis. The neurovisceral storage disorder, Niemann-Pick 
type C, sequesters cholesterol and glycosphingolipid in lysosomes. 
Filipin demonstrates the unesterified cholesterol, which cannot be 
processed, by fluorescence.[12] LDL uptake studies in fibroblasts can 
reflect LDL receptor function in homozygous FH and can predict the 
response to proprotein convertase subtilisin/kexin type 9 (PCSK9) 
neutralising monoclonal antibodies.
Discussion
This review addresses dyslipidaemia broadly to ensure recognition 
of a wide range of disorders. The majority of clinicians, however, will 
mainly manage persons at risk for atherosclerosis and pancreatitis. 
Clinical settings, in which specific lipid disorders should be 
recognised, are also briefly mentioned. The dyslipidaemias and 
dyslipoproteinaemias and their causes are summarised in Table 1.
Guidelines
Guidelines allow for reasonable practice based on CVD risk when 
serving the general population, but do not necessarily adequately 
advise on the management of severe genetic disorders. Every effort 
must be made to reach a diagnosis in the case of these disorders for best 
management decisions. This may involve referral to specialist centres.
Cost-effective testing
A full lipogram (TC, HDL cholesterol, LDL cholesterol and triglycerides), 
costing ~ZAR300, is recommended for the initial diagnosis of 
dyslipidaemia.[13] LDL cholesterol (ZAR110) or TC (ZAR80) alone can 
be used in the follow-up of patients with pure hypercholesterolaemia. A 
full lipogram is advocated for follow-up where increased LDL cholesterol 
is not the only abnormality in the lipid profile. 
Despite the proven use of these established tests in CVD risk 
prediction and management, the burden of CVD events remains 
high. Additional lipidologic (apo B) and inflammatory markers 
(C-reactive protein) may aid in addressing borderline or residual risk. 
Guidelines differ in their application. Apo B measurement (ZAR130) 
estimates LDL particle number. Whether it is superior to non-HDL 
cholesterol or total/HDL cholesterol ratio for CVD risk prediction is 
controversial. More data are clearly needed on the use of advanced 
lipoprotein tests, as well as non-HDL cholesterol and total/HDL 
cholesterol ratio as targets of therapy for common dyslipidaemias.[13]
Referral criteria
Severe dyslipidaemias, unexplained cutaneous or tendon xanthomata, 
problematic management, premature atherosclerosis and suspected 
metabolic errors all constitute reasons for referral. Heterozygous 
FH should be considered if TC concentration is >7.5 mmol/L. Most 
patients respond to statin therapy, but poorly controlled patients may 
require additional treatment following specialist work-up.
Extreme dyslipidaemias for referral and special investigation 
include: TC >15 mmol/L, LDL cholesterol >12 mmol/L and trigly-
ceride >10 mmol/L, unusually low TC (<2.0 mmol/L), LDL choles terol 
(<1.5 mmol/L) or HDL cholesterol (<0.7 mmol/L).[14]
For severe atherogenic dyslipidaemias, or those causing pancreatitis, 
effective new treatment strategies have been developed. Specialist 
centres, where clinical and laboratory expertise converge, are important 
for recognition and accurate diagnosis. Increasing consideration of 
severe or unusual lipid disorders will drive a relevant diagnostic 
repertoire, clinical expertise and patient care for South Africa.
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